Lexington Biosciences is a medical device company that is developing the HeartSentry, a new non invasive diagnostic device to measure and monitor cardiovascular health by assessing the function of a person s vascular endothelium the vital innermost lining of a person s cardiovascular system. Traditionally, this has only been measured using ultrasound and other complex, difficult to use technologies. The HeartSentry technology core research was created at the University of California Berkeley over a fifteen year period involving many studies and product iterations resulting in a portfolio of multiple pending and issued patents licensed to the company. The company is in the final stages of releasing the developed product for clinical studies. The aim is to make HeartSentry accurate, quick, and cost effective so it can become the standard of care for cardiologists, general practitioners, and ultimately patients for first line evaluation of a person s cardiovascular health. Lexington is engaged with the US FDA and other regulatory agencies on the required product approvals for the HeartSentry.
Quote | Lexington Biosciences Inc (OTCMKTS:LXGTF)
Last: | $1e-06 |
---|---|
Change Percent: | 100.0% |
Open: | $0 |
Close: | $1e-06 |
High: | $0 |
Low: | $0 |
Volume: | 20 |
Last Trade Date Time: | 12/31/1969 07:00:00 pm |
News | Lexington Biosciences Inc (OTCMKTS:LXGTF)
VANCOUVER, British Columbia, April 16, 2020 (GLOBE NEWSWIRE) -- Lexington Biosciences, Inc. (CSE: LNB) (the “Company” or “Lexington”) is pleased to announce the appointment of Donald McInnes as chief executive officer of the Company, filing the vacancy left by ...
VANCOUVER, British Columbia, Feb. 20, 2020 (GLOBE NEWSWIRE) -- Lexington Biosciences, Inc. (CSE: LNB) (the “Company” or “Lexington”) provides the following corporate update to shareholders. HeartSentry Technology The Company had been unable to secure...
Message Board Posts | Lexington Biosciences Inc (OTCMKTS:LXGTF)
Subject | By | Source | When |
---|---|---|---|
this severe decline is just so hard to | maxcaviar | investorshub | 07/28/2021 4:42:48 AM |
So sad - I had high hopes for | Vesig | investorshub | 03/15/2021 4:18:01 PM |
Can I answer with a minus number or percentage? | Stumblebum | investorshub | 02/21/2021 4:22:03 PM |
Whats the chances of a buyout for the patent? | betterdaze | investorshub | 02/12/2021 12:25:34 PM |
Lex bio is truly dead. The company no | 77Port | investorshub | 02/11/2021 3:30:01 AM |
News, Short Squeeze, Breakout and More Instantly...
Lexington Biosciences Inc Company Name:
LXGTF Stock Symbol:
OTCMKTS Market:
Lexington Biosciences Inc Website:
VANCOUVER, British Columbia, April 16, 2020 (GLOBE NEWSWIRE) -- Lexington Biosciences, Inc. (CSE: LNB) (the “Company” or “Lexington”) is pleased to announce the appointment of Donald McInnes as chief executive officer of the Company, filing the vacancy left by ...
VANCOUVER, British Columbia, Feb. 20, 2020 (GLOBE NEWSWIRE) -- Lexington Biosciences, Inc. (CSE: LNB) (the “Company” or “Lexington”) provides the following corporate update to shareholders. HeartSentry Technology The Company had been unable to secure...
VANCOUVER, British Columbia, Feb. 12, 2020 (GLOBE NEWSWIRE) -- Lexington Biosciences, Inc. (CSE: LNB) (the “Company” or “Lexington”) has allowed the license with the Lawrence Berkeley National Laboratories, which was being used in the HeartSentry technology, ...